Latest Breaking News On - Patrick barth - Page 10 : vimarsana.com

Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June 2021 ‒ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and its first-in-class anti-CD79b antibody-drug conjugate, Polivy® (polatuzumab vedotin), in non-Hodgkin lymphoma (NHL) will be presented at the 2021 ASCO Annual Meeting from 4-8 June 2021. “People with difficult-to-treat blood cancers such as non-Hodgkin lymphoma still need more options to help improve outcomes,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We are encouraged by promising data from our emerging T-cell engaging bispecific antibodies, mosunetuzumab and g

United statesNathalie meetzLevi garrawayCarlo stellaMabthera rituxanPatrick barthGazyva gazyvaroKarsten kleineInternational prognostic indexDrug administrationHead of global product developmentDrug administration breakthrough therapy designationRoche groupPharmaceuticals industryRoche group media relationsChief medical officer